Determining The Role Of DOCK8 In CD4+ T And B Cell Differentiation And Its Implications On Autosomal Recessive Hyper IgE Syndrome (AR-HIES)
Funder
National Health and Medical Research Council
Funding Amount
$512,600.00
Summary
Autosomal recessive hyper IgE (AR-HIES) syndrome due to mutations in DOCK8 is a rare primary immunodeficiency whereby patients present with susceptibility to severe and recurrent viral infections as well as an increased risk of developing cancer, severe food and environmental allergies, and atopic disease characterised by hyper IgE and extreme eosinophilia. This grant will investigate how abnormal DOCK8 function in CD4+ T cells and B cells contributes to disease pathogenesis in AR-HIES patients.
Mechanisms And Targets Of Antibody-complement Interactions That Neutralize Malaria
Funder
National Health and Medical Research Council
Funding Amount
$647,977.00
Summary
Our project aims to identify immune mechanisms that neutralize malaria from the moment of inoculation by a mosquito, before infection can become established to prevent the development of malaria disease. Furthermore, we will discover specific targets of protective immune responses. We expect this project will provide major new advances in our knowledge of human immunity to P. falciparum malaria, one of the world’s most significant causes of mortality and morbidity, and we will use this knowledge
A vaccine to prevent AIDS is urgently needed. The European Union recently awarded over 20 million euros to a European consortium, called EAVI2020, to advance multiple HIV vaccines into human testing. Five Australian HIV vaccine experts are named investigators on this award to provide advanced laboratory analyses and intellectual input into the 5 year program if this NHMRC-EU Collaborative Research Grant is successful.
Utilising Human Primary Immunodeficiencies To Study Lymphocyte Differentiation
Funder
National Health and Medical Research Council
Funding Amount
$429,346.00
Summary
Human immunodeficiencies are diseases arising from naturally occurring mutations. In this instance, the specific genes mutated in the immunodeficiencies we study have been identified. However, it is unclear how defects in these genes make an individual manifest as an immune deficient state, rendering them vulnerable to disease. By studying immune cells from these individuals we hope to uncover the normal function of these genes and subsequently provide for new therapies for these conditions.
RELapses PrevENTion In Chronic Autoimmune Disease: Common Mechanisms And Co-morbidities (RELENT)
Funder
National Health and Medical Research Council
Funding Amount
$499,837.00
Summary
Treatment of people with chronic autoimmune and inflammatory diseases is not optimal, as we do not know how intensively to treat people, and current treatments often have significant side effects. The RELENT program aims, using multiple approaches, to gain a deeper and more useful knowledge of why these diseases are occuring, what might indicate that disease requires more treatment, and which treatments will be most targeted and have the fewest side effects.
I am an infectious diseases physician and virologist/immunologist focused on developing and testing vaccines against the AIDS virus. I intend to achieve this by advancing novel vaccine concepts that stimulate broad and potent immunity and evaluating these vaccines in rigorous laboratory models and then moving them towards clinical trials.
A vaccine for hepatitis C virus (HCV) is not yet available. Immune responses that are able to protect against infection are possible, making the production of a vaccine a realistic goal. We have produced a unique HCV vaccine and are now poised to test our vaccine in novel humanised animal models. Our research will allow us to determine the immune responses responsible for providing protection against HCV. Our data will be highly significant for future HCV vaccine studies in humans.
Determining The Essential Regulators Of Antibody Production
Funder
National Health and Medical Research Council
Funding Amount
$768,612.00
Summary
Plasma cells produce the antibodies that are essential to protect us from pathogenic microorganisms and provide the basis for the beneficial effects of vaccination. Plasma cells can also cause disease through the production of antibodies against our own body, for example in Lupus and in the blood cell cancer multiple myeloma . Our research aims to understand the genetic regulation of antibody production, with an aim to "switch off" inappropriate antibody supply in disease.